Video

TEXT/SOFT Findings in HR-Positive Breast Cancer

For High-Definition, Click

The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) studies were complementary phase III, randomized clinical trials that evaluated premenopausal women with hormone receptor—positive early breast cancer. In both trials, all patients received ovarian suppression. In TEXT, patients were randomized to receive either tamoxifen or exemestane if chemotherapy was given. In SOFT, patients were randomized to receive tamoxifen alone or ovarian suppression with tamoxifen or exemestane.

A joint analysis of the two studies demonstrated that adjuvant use of ovarian function suppression plus exemestane reduced the relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen, according to findings presented at the 2014 ASCO Annual Meeting. Cancer-free survival at 5 years was 91.1% in the exemestane arm compared with 87.3% in the tamoxifen arm. Similar 5-year overall survival rates occurred in both arms, with a 95.9% survival with exemestane compared with 96.9% with tamoxifen.

The rationale for the study was based on evidence that patients with high-risk, estrogen receptor—positive disease may benefit from ovarian suppression and tamoxifen, followed by a switch to exemestane therapy. This strategy spares individuals from experiencing too many adverse events at once, explains Hope S. Rugo, MD.

Monitoring serum estradiol levels in 30-year-old individuals with high-risk disease is important, as these levels are believed to be part of tumor control, Sara Hurvitz, MD, mentions. Additionally, ovarian suppression plays an important role in high-risk premenopausal patients. Patients in their 30s and 40s need to consider the long-term side effects of these therapies, and clinicians must convince women that the benefits outweigh the risks, emphasizes Dialecti Voudouris, MD.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity